Apyx Medical is preparing for the commercial availability of its latest innovation—the Apyx body contouring system, branded as AYON—following FDA clearance for a broad range of aesthetic treatments. This one-platform technology is designed to help surgeons who perform fat reduction, skin tightening, and other body contouring treatments, combining a number of technologies into one advanced device.

The heart of AYON is Apyx's proprietary Renuvion technology, which uses helium plasma and radiofrequency energy to tighten and contract loose skin. The system also includes ultrasound-assisted liposuction and electrocoagulation, enabling the removal of excess tissue and contouring to be done more effectively. With these features, AYON is poised to meet the growing needs of patients who undergo significant body transformation.

The Apyx body contouring system will be aimed towards a targeted commercial launch in the second half of 2025, in which the company will be making the system available to targeted aesthetic and plastic surgeons.

“The aesthetics market is anticipating a significant surge in body contouring treatments next year," Apyx Medical CEO Charlie Goodwin stated. “Over 15 million patients already taking GLP-1RA anti-obesity medications are seeing rapid fat loss, and most are now looking for effective treatments for tightening loose, sagging skin. The AYON system addresses those needs in one platform."

Aesthetic Market Trends with GLP-1Ras

The treatment with GLP-1 receptor agonist drugs like Ozempic and Wegovy has revolutionized patient profiles in the aesthetic industry. Though the patients lose a considerable amount of weight within a few months, they are left with loose skin—particularly on the tummy, arms, and thighs. This has created a new need for skin tightening and body contouring procedures.

Apyx Medical's AYON system appears to be set to meet this emerging market. The Apyx body contouring system is able to accommodate both minimally invasive and traditional surgical procedures, which can accommodate the full spectrum of treatments, ranging from minor recontouring to more thorough body sculpting.

Market figures by GlobalData project that the aesthetic body contouring device market will grow from $721 million in 2024 to nearly $978 million by 2034. Non-invasive and minimally invasive devices will be the trend, with nearly 60% of market share coming from non-invasive solutions.

An Emerging, Competitive Climate

The North American body contouring devices market is competitive, with market leaders providing sought-after solutions like CoolSculpting by market leaders Allergan Aesthetics (a subsidiary of AbbVie). AYON is distinct as it is multifunctional and comes with the additional advantage of Renuvion.

In the UK, the British Association of Aesthetic Plastic Surgeons (BAAPS) recently released statistics of a 5% increase in cosmetic surgery in 2024, including liposuction, abdominoplasty, and other body-focused procedures. With patients all over the world wishing to preserve the results of severe weight loss, technology like the AYON is more and more relevant.

Surgeons and Patients Gain from Integration

What makes the Apyx body contouring system different from the others in the market is its effectiveness and range. To clinics, it offers a single machine that reduces the utilization of several machines, saves space, and facilitates training.

To patients, the integration of the technologies may mean shorter treatment time, less cutting, and better post-procedure results. As aesthetics moves towards increasingly result- and patient-focused treatments, AYON may be a flagship device for result-based practices.

With FDA clearance in hand and strategic roll-out on standby, Apyx Medical is positioned at the forefront of an increasingly fast-moving, opportunity-filled market.